Live
- Delhi court grants 30-day extension to police to conclude probe in Parliament security breach case
- Cash, liquor, drugs valued at Rs 321 crore confiscated in Punjab
- Gunfight breaks out in J&K's Sopore
- BJP aims to improve tally, Congress plays Vokkaliga card as 14 seats in K'taka go to polls on Friday
- IPL 2024: Have to be prepared for the KKR challenge, says PBKS spin bowling coach Sunil Joshi
- Advocate Dehadrai withdraws defamation suit against Mahua Moitra in Delhi HC
- Man thrashed, thrown off 8th floor of NDMC building in Delhi; 2 held for murder
- Punjab CM Maryam Nawaz reviews police passing out parade in uniform
- RBI issues alert against prepaid payment instruments by illegal entities
- Hackers attacked Indian firms on average 2,444 times per week in last 6 months: Report
Dr Reddy's launches anti-smoking drug
Dr. Reddy's Laboratories Ltd on Thursday announced the launch in the US market of Bupropion Hydrochloride Extended-Release Tablets, USP (SR), a therapeutically equivalent generic version of Zyban, indicated for treatment of nicotine dependence as an aid to smoking cessation.
Hyderabad: Dr. Reddy's Laboratories Ltd on Thursday announced the launch in the US market of Bupropion Hydrochloride Extended-Release Tablets, USP (SR), a therapeutically equivalent generic version of Zyban, indicated for treatment of nicotine dependence as an aid to smoking cessation.
According to a release by the city-based drug maker, the generic Zyban has been approved by the U S Food and Drug Administration (USFDA).
The Zyban brand and generic had U.S. sales of approximately $5.4 million MAT (moving annual turnover) for the most recent 12 months ending in June 2019 DRL said quoting the market reports.
Dr. Reddy's Bupropion Hydrochloride Extended-Release Tablets, USP (SR) are available as 150 mg dosage strength in bottle count sizes of 60.
Zyban tablets are indicated for the treatment of nicotine dependence as an aid to smoking cessation.
